NCT04610970View on ClinicalTrials.gov

A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）

PHASE2UnknownINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

June 30, 2022

Conditions
Diffuse Large B-cell Lymphoma
Interventions
DRUG

TQ-B3525 tablets

TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.

Trial Locations (2)

100021

NOT_YET_RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

100730

RECRUITING

Beijing Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY